SIS2 Antibody

What is the SIS2 study and what are its primary objectives?

The Schools Infection Survey 2 (SIS2) is a cross-sectional surveillance study conducted in England to estimate the prevalence of SARS-CoV-2 antibodies in primary (4-11 years) and secondary (11-18 years) school children. It was conducted by the Office for National Statistics (ONS) in partnership with the London School of Hygiene and Tropical Medicine, working with the Department for Education and funded by the UK Health Security Agency .

The primary objectives of SIS2 were to:

• Determine the national and regional prevalence of SARS-CoV-2 antibodies in school-aged children

• Distinguish between infection-induced and vaccine-induced immunity

• Track changes in antibody prevalence over time with three planned testing rounds

• Inform policies to protect school pupils and staff

• Support school recovery policies following the pandemic

Unlike its predecessor (SIS1), which focused on COVID-19 transmission in schools, SIS2 expanded its scope to produce robust national and regional estimates of antibody prevalence .

What biological samples were collected in SIS2 and how were they processed?

SIS2 utilized oral fluid (saliva) samples as the primary biological specimen for antibody testing. The collection process involved:

• Participants placing a small sponge into their mouth for two minutes to collect saliva

• Samples being processed by anonymizing them using barcodes

• Laboratory staff extracting the oral fluid by adding elution buffer and agitating the swab

• Centrifuging the resulting eluate and storing it at -30°C until testing

The oral fluid samples were then tested for SARS-CoV-2 antibodies using an in-house Immunoglobulin G antibody capture enzyme immunoassay (EIA) based on a solid-phase anti-human IgG with either:

• An HRP-conjugated Nucleoprotein (N) antigen probe, or

• An HRP-conjugated Spike (S) S1 subunit antigen probe (produced and provided by The Francis Crick Institute)

This non-invasive collection method was particularly suitable for the school-based setting and pediatric population being studied.

What were the key findings regarding antibody prevalence in the SIS2 study?

The SIS2 study revealed significant insights into SARS-CoV-2 antibody prevalence among school-aged children during November/December 2021 in England. After weighting for age, sex, and ethnicity, and adjusting for assay accuracy, the study found:

Primary School Students (all unvaccinated):

• National prevalence: 40.1% (95% CI 37.3-43.0)

• Higher prevalence with increasing age (p < 0.001)

• Higher prevalence in urban compared to rural schools (p = 0.01)

Secondary School Students:

These findings indicate substantially higher SARS-CoV-2 antibody prevalence than might have been detected through clinical case reporting alone, suggesting significant undetected or asymptomatic infections among school-aged children.

How was the sampling methodology designed to ensure representativeness in SIS2?

SIS2 employed a sophisticated two-stage cluster sampling approach to generate nationally and regionally representative estimates of antibody prevalence:

First Stage: Stratification by regions and selection of local authorities
Second Stage: Selection of schools according to a stratified sample within selected local authorities

The sample size calculation assumed:

• The most statistically conservative scenario of 50% antibody prevalence (yielding the widest confidence intervals)

• ±5% precision with 95% confidence at a regional level for both primary and secondary schools

• Average populations of 280 students in primary and 965 in secondary schools

• School-level response rate of 15% based on administrative data and prior SIS1 experience

• Design effect of 2.3 (based on SIS1) to account for clustering within schools

This resulted in a target sample of 13 primary and 7 secondary schools in each of the nine regions in England, for a total of 180 schools nationally. The final analyzed sample included 4,980 students from 117 state-funded schools (2,706 from 83 primary schools, 2,274 from 34 secondary schools) .

All estimates were weighted to be representative at regional and national levels, accounting for:

• Sampling design

• School-level response rate

• Age

• Sex

• Ethnicity

• Free-school meals eligibility

The 95% confidence intervals were calculated using robust standard errors to account for the cluster sampling design, enhancing the statistical rigor of the prevalence estimates.

How does the oral fluid antibody assay compare with serum-based methods, and what adjustments were made to account for assay performance?

The oral fluid-based antibody detection method used in SIS2 offers significant advantages for large-scale pediatric studies but differs from traditional serum-based assays in performance characteristics:

Assay Performance Characteristics:

• Nucleoprotein (N) assay in unvaccinated children and adults:

  • Sensitivity: 80%

  • Specificity: 99%

• Spike (S1) assay in unvaccinated individuals:

  • Sensitivity: 75%

  • Specificity: 98%

Methodological Adjustments:

• For unvaccinated children, presence of either N-antibody and/or S-antibody was considered evidence of past infection

• Prevalence estimates in unvaccinated children were mathematically adjusted to reflect the known sensitivity (80%) and specificity (99%) of the oral fluid assay compared to serum

• For vaccinated participants, only N-antibodies were considered as evidence of past infection

• No adjustments were made to estimate prevalence in vaccinated children due to the very high S-antibody levels achieved by mRNA vaccines and the consequent high correlation between serum and oral fluid antibody levels

The researchers verified that potential sources of bias, including amplification bias during phage infection and codon bias at the nucleotidic level, had negligible impact on the results, confirming that the observed selection modes primarily arose from ligand binding .

What approaches were used to distinguish between infection-induced and vaccine-induced antibodies?

SIS2 implemented a sophisticated dual-assay approach to differentiate between infection-induced and vaccine-induced antibodies:

• Assay Targeting Strategy:

  • Nucleocapsid (N) protein antibody assay: Detects antibodies only produced following natural infection

  • Spike (S) protein antibody assay: Detects antibodies produced following either natural infection or vaccination

• Interpretation Framework:

  • Unvaccinated individuals: Presence of either N-antibodies or S-antibodies indicated prior infection

  • Vaccinated individuals: Only N-antibodies were used to indicate prior infection, as S-antibodies would be present due to vaccination regardless of infection history

• Validation Through Data Linkage:

  • Participant data was linked to national laboratory reports of SARS-CoV-2 PCR and lateral flow device tests (Second Generation Surveillance System, SGSS)

  • Linkage to the National Immunisation Management Service (NIMS) database identified COVID-19 vaccination status and date of vaccination

  • Students were classified as vaccinated if they had received ≥1 COVID-19 vaccine dose ≥14 days before their antibody test

This approach allowed researchers to disentangle the complex immune response landscape during a period when both natural infections and vaccinations were contributing to population immunity among school-aged children.

What computational models can be applied to analyze antibody specificity profiles from high-throughput data?

Advanced computational approaches can significantly enhance the analysis of antibody specificity data from studies like SIS2, particularly when designing antibodies with custom specificity profiles:

Biophysics-Informed Neural Network Models:
A sophisticated approach involves using neural networks trained on experimental antibody selection data to predict binding specificities. Such models:

• Associate distinct binding modes with each potential ligand

• Enable prediction and generation of specific variants beyond those observed in experiments

• Can disentangle multiple binding modes associated with specific ligands

The mathematical framework typically involves:

• Defining an energy function (E_sw) that characterizes the binding affinity of a sequence (s) to a ligand associated with mode (w)

• Parameterizing this energy function using a shallow dense neural network

• Optimizing model parameters globally to capture the evolution of antibody populations across several experiments

• Inferring initial library abundances during training

Once trained, these models can:

• Simulate experiments with custom sets of selected/unselected modes

• Predict the expected probability of selection for variant sequences

• Generate novel antibody sequences with predefined binding profiles (either cross-specific or specific)

This computational approach offers particular value when very similar epitopes need to be discriminated, or when these epitopes cannot be experimentally dissociated from other epitopes present in the selection process.

How can antibody study data be integrated with epidemiological analyses for public health insights?

Integrating antibody study data with broader epidemiological analyses provides crucial public health insights:

Data Integration Approaches:

• Direct Deterministic Linkage:

  • SIS2 implemented personal identifying information linkage to national laboratory reports (SGSS) and vaccination records (NIMS)

  • This allowed correlation between reported cases, vaccination status, and antibody presence

• Comparative Analysis:

  • Antibody prevalence by age, region, and demographic factors allows for identification of under-detected infections

  • In SIS2, the 40.1% prevalence in unvaccinated primary school children suggested significant undetected infections in this population

• Temporal Tracking:

  • Multiple sampling rounds (SIS2 planned three rounds) allow tracking of antibody persistence and waning

  • Changes in prevalence over time can indicate new infection waves or antibody decay

• Demographic Stratification:

  • Analyzing prevalence by urban/rural setting revealed significantly higher rates in urban primary schools

  • This information helps target interventions to higher-risk settings

• Vaccination Effect Assessment:

  • The stark difference between vaccinated (97.5%) and unvaccinated (71.5%) secondary students provides evidence of vaccination effectiveness

  • This data supports vaccination policy decisions for pediatric populations

The integration of antibody data with traditional surveillance creates a more complete picture of population exposure and immunity, particularly valuable for age groups like children where symptomatic disease may be less common and thus under-reported through clinical surveillance systems.

What quality control measures are essential when conducting large-scale school-based antibody studies?

Large-scale school-based antibody studies like SIS2 require rigorous quality control measures to ensure valid and reliable results:

Sample Collection and Processing Controls:

• Standardized collection protocols (2-minute oral fluid collection with small sponge)

• Appropriate protective clothing for study staff during sample collection

• Immediate processing with elution buffer and centrifugation

• Storage at -30°C until testing to prevent degradation

Laboratory Quality Assurance:

• Sample anonymization using barcodes to prevent bias in interpretation

• Validated assays with known sensitivity and specificity (80%/99% for N-protein, 75%/98% for S-protein)

• Assessment of potential amplification bias during phage infection

• Evaluation of potential codon bias at the nucleotidic level

• Consistent laboratory protocols across all testing sites

Statistical Quality Control:

• Adjustment of prevalence estimates to account for known test performance characteristics

• Weighting of results to address potential selection bias

• Calculation of robust standard errors to account for cluster sampling design

• Evaluation of non-response bias through comparison with demographic data

Data Linkage Verification:

• Validation of linkage accuracy between antibody results and national testing/vaccination records

• Assessment of temporal relationships (e.g., ensuring vaccinations preceded antibody tests by ≥14 days)

Implementation of these quality control measures is essential for generating reliable prevalence estimates that can inform public health policy and educational sector planning.

How should researchers approach the ethical considerations of school-based antibody testing studies?

School-based antibody testing studies involve unique ethical considerations due to the pediatric population, educational setting, and potential implications of results:

Consent and Assent Processes:

• SIS2 implemented an online consent form for secondary students (Year 12 and 13)

• Clear information sheets were provided explaining the study purpose, procedures, and voluntary nature

• Explicit statements confirmed that schools and pupils could withdraw at any round of testing

• Even after withdrawal, previously collected data could still be used unless participants explicitly requested otherwise

Incentives and Compensation:

• SIS2 offered a £5 e-voucher to secondary school pupils after each completed test or questionnaire

• This modest incentive acknowledged participation without being coercive

Data Privacy and Confidentiality:

• Personal information was collected but limited to names, dates of birth, contact details, and health information

• Samples were anonymized using barcodes

• Assurance that only people involved in running the study would use participant information

• Commitment that any published data would not identify individuals or schools

Results Communication:

• Commitment to report individual oral fluid antibody test results to participants

• Acknowledgment that results might take several months to process

• Clear explanation of what the results meant, including the important caveat that it was "currently unclear how much protection this gives a person"

Broader Ethical Framework:

• Balance between knowledge generation for public good and participant burden

• Recognition of additional questionnaires asking about health and wellbeing

• Clear articulation of study benefits: informing policies to protect pupils and staff

Researchers should develop robust ethical frameworks addressing these considerations while maintaining scientific rigor and validity of their studies.

What innovations in antibody detection methods could enhance future school-based surveillance studies?

Future school-based antibody surveillance studies could benefit from several methodological innovations:

Multiplex Assay Development:

• Simultaneous detection of antibodies against multiple SARS-CoV-2 antigens (Spike, Nucleocapsid, RBD)

• Integration with testing for other respiratory pathogens to create comprehensive respiratory infection profiles

• Inclusion of antibody isotype and subclass determination (IgG, IgM, IgA) for more detailed immune response characterization

Point-of-Care Testing:

• Development of rapid, on-site oral fluid antibody tests with comparable sensitivity/specificity to laboratory methods

• Digital result capturing for immediate data integration

• Reduced time from collection to results, enhancing participant engagement

Advanced Bioinformatic Integration:

• Implementation of biophysics-informed models to analyze antibody specificity profiles at scale

• Automated epitope mapping from antibody binding patterns

• Machine learning algorithms for predicting antibody longevity based on initial measurements

Enhanced Sample Collection:

• Development of more absorbent oral fluid collection devices to improve sample quality

• Standardized collection protocols that control for time since eating/drinking

• Self-collection options suitable for take-home use to enable more flexible sampling strategies

Longitudinal Monitoring Tools:

• Deployable surveillance kits for periodic self-collection

• Digital platforms for tracking antibody persistence over time

• Integration with symptom monitoring and behavioral data collection

These innovations could significantly enhance the quality, efficiency, and utility of future school-based antibody surveillance efforts, potentially enabling more frequent and widespread monitoring with less disruption to educational activities.

How can the methodological approaches from SIS2 be adapted for surveillance in other institutional settings?

The methodological framework established in SIS2 can be effectively adapted for antibody surveillance in various institutional settings:

Healthcare Facilities:

• Similar oral fluid sampling for healthcare workers to monitor exposure patterns

• Stratified sampling within different departments to understand transmission dynamics

• Linkage to patient exposure data to assess infection control effectiveness

Long-Term Care Facilities:

• Simplified collection protocols suitable for elderly populations

• Integration with resident vaccination records to distinguish immunity sources

• Regular sampling to track waning immunity in vulnerable populations

Workplace Settings:

• Two-stage sampling approach adapted to organizational structures (departments, locations)

• Inclusion of occupational exposure factors in analysis frameworks

• Remote collection options for distributed workforces

University Campuses:

• Adaptation of sampling frameworks to account for communal living arrangements

• Integration with campus PCR/antigen testing programs

• Analysis stratified by program of study to identify differential exposure risks

Adaptation Principles:

• Maintain the statistical rigor of two-stage sampling but modify to reflect institutional hierarchies

• Adjust weighting factors to account for the specific demographics of the population

• Maintain oral fluid sampling approach for acceptability and compliance

• Preserve dual-assay approach to distinguish infection from vaccination when relevant

• Adapt questionnaire components to capture setting-specific exposure factors

The non-invasive nature of oral fluid collection makes the SIS2 methodology particularly adaptable to settings where repeated surveillance is desired and where minimizing disruption to normal activities is important.

What insights from antibody specificity studies can inform vaccine development strategies?

Advanced understanding of antibody specificity from studies like SIS2 and computational modeling approaches can significantly inform vaccine development strategies:

Immune Response Characterization:

• SIS2-type studies provide population-level data on antibody responses to both infection and vaccination

• The different prevalence in vaccinated (97.5%) versus infection-acquired immunity (71.5% in unvaccinated) informs efficacy comparisons

• These insights help identify which antigen components elicit the most robust responses

Computational Epitope Mapping:

• Biophysics-informed models can identify binding modes associated with neutralizing versus non-neutralizing antibodies

• This knowledge can guide antigen design to focus immune responses on protective epitopes

• By understanding binding energetics, vaccine antigens can be engineered to maximize production of antibodies with desired specificity profiles

Variant-Specific Considerations:

• Analysis of cross-reactivity patterns reveals which antibodies maintain binding across variants

• This informs which conserved epitopes should be targeted in next-generation vaccines

• Models that can generate antibodies with custom specificity profiles provide templates for desired vaccine-induced responses

Vaccination Strategy Refinement:

• Age-stratified antibody data from studies like SIS2 reveals differential responses across age groups

• These insights can inform age-specific dosing or booster recommendations

• Urban/rural differences in baseline seropositivity might suggest tailored vaccination approaches by region

Development Process Enhancement:

• Use computational models to predict antibody responses to candidate antigens

• Design antigens that specifically elicit antibodies with optimized binding profiles

• Test predicted responses in small-scale studies before large clinical trials

• Integrate population serosurveillance data to identify gaps in protection

• Refine boosting strategies based on antibody persistence patterns

By leveraging the methodological approaches from SIS2 and the computational advances in antibody specificity modeling, vaccine development can become more targeted and efficient, potentially leading to improved protection against emerging pathogens and variants.